Absolute configuration of (−)‐4‐(3,4‐di­chloro­phenyl)‐4‐(2‐pyridyl)­butanoic acid: essential information to determine crucial steric features of ­arpromidine‐type hist­amine H2 receptor agonists

The structural information gained from the study of the chiral building block (R)‐(?)‐4‐(3,4‐di­chloro­phenyl)‐4‐(2‐pyridyl)­butanoic acid–l ‐(?)‐ephedrine [methyl(1‐hydroxy‐1‐phenyl­prop‐2‐yl)ammon­ium 4‐(3,4‐di­chloro­phenyl)‐4‐(2‐pyrid­yl)but­an­oate], C₁₀H₁₆NO⁺·C₁₅H₁₂Cl₂NO₂^?, can be used to deduce the absolute configuration of highly potent arpromidine‐type hist­amine H₂ receptor agonists, as the chiral butanoic acid can be converted to (R)‐(?)‐3‐(3,4‐di­chloro­phenyl)‐3‐(2‐pyridyl)­propyl­amine and to the corresponding R‐configured arpromidine analogue.     

A 1,2,4‐diazaphospholane complex of rhodium

The crystal structure of a prospective olefin catalyst, namely {2‐[1‐acetyl‐5‐(2‐hydroxy­phenyl)‐4‐phenyl‐1,2,4‐di­aza­phospholan‐3‐yl]­phenyl acetate‐κP}chloro­(η⁴‐cyclo­octa‐1,5‐diene)rhodium(I) di­chloro­methane solvate, [RhCl(C₈H₁₂)(C₂₄H₂₃N₂O₄P)]·CH₂Cl₂, has been determined at 173 K. The five‐membered heterocycle of the phosphine ligand is in a slightly distorted twist conformation. An intramolecular N1—H1⃛Cl1 hydrogen bond contributes to the adopted conformation and may additionally participate in secondary interactions with substrates during catalysis.     

Hydro­gen‐bonding patterns in two structural isomers of 3,6‐bis(2‐chloro­phenyl)‐1,4‐di­hydro‐1,2,4,5‐tetrazine

Two structural isomers, 3,6‐bis(2‐chloro­phenyl)‐1,4‐di­hydro‐1,2,4,5‐tetrazine, (I), and 3,5‐bis(2‐chloro­phenyl)‐4‐amino‐1H‐1,2,4‐triazole, (II), both C₁₄H₁₀Cl₂N₄, form chain‐like structures in the solid state, stabilized by N—H⋯N and N—H⋯Cl hydrogen bonds. A contribution from weak interactions to the strong hydrogen‐bond network is observed in both structures. The secondary graph sets for intermolecular hydrogen bonds [(11) for (I) and (12) for (II)] indicate the similarity between the networks.     

Two 2,2‐dihalo‐N‐(1‐phenyl­ethyl)­cyclo­propane‐1‐carbox­amides

The crystal structures of (1R,1′S)‐2′,2′‐di­chloro‐N‐(1‐phenyl­ethyl)­cyclo­propane‐1′‐carbox­amide, C₁₂H₁₃Cl₂NO, (I), and (1R,1′R)‐2′,2′‐di­fluoro‐N‐(1‐phenyl­ethyl)­cyclo­propane‐1′‐car­box­amide, C₁₂H₁₃F₂NO, (II), have been determined. Both crystals contain two independent mol­ecules with different conformations of the phenyl­ethyl groups. In the crystals of both compounds, the mol­ecules are linked together by N—H⃛O hydrogen bonds, thus forming chains in the a direction.     

New electron‐deficient chiral phosphines: (4R,5R)‐1,3‐bis(trifluoromethanesulfonyl)perhydro‐1,3,2‐benzodiazaphosphol‐2‐yl] substituted amines

Three chiral electron‐deficient phosphine ligands, [(4R,15R)‐,3‐bis­(tri­fluoro­methane­sulfonyl)­per­hydro‐1,3,2‐benzodiazaphosphol‐2‐yl]­diethyl­amine, C₁₂H₂₀F₆N₃O₄PS₂, (IIIa), [(4R,5R)‐1,3‐bis­(tri­fluoro­methane­sulfonyl)­per­hydro‐1,3,2‐benzodi­aza­phosphol‐2‐yl]­di­methyl­amine, C₁₀H₁₆F₆N₃O₄PS₂, (IIIb), and bis­[(4R,5R)‐1,3‐bis­(tri­fluoro­methane­sulfonyl)­per­hydro‐1,3,2‐benzodi­aza­phosphol‐2‐yl]­methyl­amine, (IV), as the chloroform solvate, C₁₇H₂₃F₁₂N₅O₈P₂S₄·0.98CHCl₃, have been prepared from (1R,2R)‐N,N′‐bis­(tri­fluoro­methane­sulfonyl)‐1,2‐cyclo­hexane­di­amine and diethyl phosphor­amido­us dichloride, dimethyl phosphoramidous dichloride or methyl imidodi­phosphorus tetrachloride. The π‐acceptor abilities of these new types of ligands have been evaluated by X‐ray determination of the P—N bond lengths; it has been found that the most promising ligand is the bis­(phosphine) (IV).     

Di­propyl 3,6‐di­phenyl‐1,2‐di­hydro‐1,2,4,5‐tetrazine‐1,2‐di­carboxyl­ate

The title compound, C₂₂H₂₄N₄O₄, was prepared from propyl chloro­formate and 3,6‐di­phenyl‐1,2‐di­hydro‐s‐tetrazine. This reaction yields the title compound rather than di­propyl 3,6‐di­phenyl‐1,4‐di­hydro‐s‐tetrazine‐1,4‐di­carboxyl­ate. The 2,3‐di­aza­buta­diene group in the central six‐membered ring is not planar; the C=N double‐bond length is 1.285 (2) Å, and the average N—N single‐bond length is 1.401 (3) Å, indicating a lack of conjugation. The ring has a twist conformation, in which adjacent N atoms lie 0.3268 (17) Å from the plane of the ring. The mol­ecule has twofold crystallographic symmetry.     

(Z)‐2‐Methylbuten‐1‐yl(aryl)iodonium trifluoromethanesulfonates containing electron‐withdrawing groups on the aryl moiety

The crystal structures of [(Z)‐2‐methyl­but‐1‐en‐1‐yl]­[4‐(tri­fluoro­methyl)­phenyl]­iodo­nium tri­fluoro­methane­sulfonate, C₁₂H₁₃F₃I⁺·CF₃O₃S^?, (I), (3,5‐di­chloro­phenyl)­[(Z)‐2‐methyl­but‐1‐en‐1‐yl]­iodo­nium tri­fluoro­methane­sulfonate, C₁₁H₁₂­Cl₂I⁺·CF₃O₃S^?, (II), and bis{[3,5‐bis­(tri­fluoro­methyl)­phenyl][(Z)‐2‐methyl­but‐1‐en‐1‐yl]­iodo­nium} bis­(tri­fluoro­methane­sulfonate) di­chloro­methane solvate, 2C₁₃H₁₂F₆I⁺·­2CF₃­O₃S^?·CH₂Cl₂, (III), are described. Neither simple acyclic β,β‐di­alkyl‐substituted alkenyl­(aryl)­idonium salts nor a series containing electron‐deficient aryl rings have been described prior to this work. Compounds (I)–(III) were found to have distorted square‐planar geometries, with each I atom interacting with two tri­fluoro­methane­sulfonate counter‐ions.     

tert‐Butyl (6S)‐4‐hydroxy‐6‐isobutyl‐2‐oxo‐1,2,5,6‐tetra­hydropyridine‐1‐carboxyl­ate and tert‐butyl (4R,6S)‐4‐hydroxy‐6‐iso­butyl‐2‐oxopiperidine‐1‐carboxyl­ate

X‐ray studies reveal that tert‐butyl (6S)‐6‐iso­butyl‐2,4‐dioxo­piperidine‐1‐carboxyl­ate occurs in the 4‐enol form, viz. tert‐butyl (6S)‐4‐hydroxy‐6‐iso­butyl‐2‐oxo‐1,2,5,6‐tetra­hydropyri­dine‐1‐carboxyl­ate, C₁₄H₂₃NO₄, when crystals are grown from a mixture of di­chloro­methane and pentane, and has an axial orientation of the iso­butyl side chain at the 6‐position of the piperidine ring. Reduction of the keto functionality leads predominantly to the corresponding β‐hydroxy­lated δ‐lactam, tert‐butyl (4R,6S)‐4‐hydroxy‐6‐iso­butyl‐2‐oxo­piperidine‐1‐car­boxyl­ate, C₁₄H₂₅NO₄, with a cis configuration of the 4‐hydroxy and 6‐iso­butyl groups. The two compounds show similar molecular packing driven by strong O—H⋯O=C hydrogen bonds, leading to infinite chains in the crystal structure.     

Novel heterocyclic inhibitors of matrix metalloproteinases: three 6H‐1,3,4‐thiadiazines

The title compounds, (2S)‐N‐[5‐(4‐chloro­phenyl)‐2,3‐di­hydro‐6H‐1,3,4‐thia­diazin‐2‐yl­idene]‐2‐[(phenyl­sulfonyl)­amino]­pro­pan­amide, C₁₈H₁₇ClN₄O₃S₂, (I), (2R)‐N‐[5‐(4‐fluoro­phenyl)‐6H‐1,3,4‐thia­diazin‐2‐yl]‐2‐[(phenyl­sulfonyl)amino]­propan­amide, C₁₈H₁₇FN₄O₃S₂, (II), and (2S)‐N‐[5‐(5‐chloro‐2‐thienyl)‐6H‐1,3,4‐thia­diazin‐2‐yl]‐2‐[(phenyl­sulfonyl)­amino]­propan­amide, C₁₆H₁₅ClN₄O₃S₃, (III), are potent inhibitors of matrix metalloproteinases. In all three compounds, the thia­diazine ring adopts a screw‐boat conformation. The mol­ecules of compound (I) show a short intramolecular N_Ala—H?N_exo hydrogen bond [N?N 2.661 (3) Å] and are linked into a chain along the c axis by N_endo—H?S_endo and N_endo—H?O_Ala hydrogen bonds [N?S 3.236 (3) and N?O 3.375 (3) Å] between neighbouring mol­ecules. In compound (II), the mol­ecules are connected antiparallel into a chain along the a axis by N_exo—H?O_Ala and N_Ala—H?N_endo hydrogen bonds [N?O 2.907 (6) and N?N 2.911 (6) Å]. The mol­ecules of compound (III) are dimerized antiparallel through N_exo—H?N_endo hydrogen bonds [N?N 2.956 (7) and 2.983 (7) Å]. The different hydrogen‐bonding patterns can be explained by an amido–imino tautomerism (prototropic shift) shown by different bond lengths within the 6H‐1,3,4‐thia­diazine moiety.     

(4S,5S)‐(+)‐4‐Hydro­xy­methyl‐2,5‐di­phenyl­oxazoline

The absolute configuration of the title compound, alter­natively called (+)‐(4,5‐di­hydro‐2,5‐di­phenyl­oxazol‐4‐yl)­methanol, C₁₆H₁₅NO₂, has been confirmed as 4S,5S. The hydroxy­methyl group and phenyl ring at the asymmetric C atoms exhibit β and α orientations, respectively. The exocyclic C—C bonds at the asymmetric C atoms are mutually anticlinal (?ac). The hydroxyl group and the N atom of the oxazoline ring are involved in an intermolecular hydrogen bond leading to chains of mol­ecules.     

cis‐Di­chloro(5,8‐dioxa‐2,11‐dithia[12]‐o‐cyclo­phane)­palladium(II)

The preparation and crystal structure of the title compound, cis‐di­chloro­[6,9‐dioxa‐3,12‐di­thia­bi­cyclo­[12.4.0]­octadeca‐14,‐16,­18(1)‐tri­ene‐S,S′]­palladium(II), [PdCl₂(C₁₄H₂₀O₂S₂)], are described. The Pd atom has a square‐planar environment, coordinated to two S atoms of the di­thia­dioxa macrocycle and to two Cl^? ions. The non‐coordinating O atoms are oriented away from the metal coordination plane. Upon complexation, a bicyclic chelate structure, which consists of a seven‐ and an eleven‐membered ring, is formed.     

(Z)‐7‐Chloro‐3‐[(3‐chloro­phenyl)­methyl­idene]‐4‐p‐tosyl‐3,4‐di­hydro‐2H‐1,4‐benzoxazine

In the title compound, C₂₂H₁₇Cl₂NO₃S, the mol­ecule is a substituted 3,4‐di­hydro‐2H‐1,4‐benzoxazine compound which has three phenyl rings which are essentially planar. The 3,4‐di­hydro‐2H‐oxazine part of the mol­ecule is fused to the benzo ring and has a half‐boat conformation; the dihedral angle between the planar part of the oxazine ring and the benzo ring is 10.2 (2)°. The (3‐chloro­phenyl)­methyl­idene substituent has a Z configuration in relation to the ring N atom of the oxazine moiety. Interestingly, the p‐toluenesulfonyl (p‐tosyl) substituent on the ring N atom protrudes away from the 3‐­chloro­phenyl substituent thus avoiding any steric interaction.     

Derivatives of 4‐(2‐hydro­xy­lphenyl)‐2‐phenyl‐2,3‐di­hydro‐1,5‐benzothiazepine

In the structures of 2‐(4‐chloro­phenyl)‐4‐(2‐hydroxyphenyl)‐2,3‐di­hydro‐1,5‐benzo­thia­zepine, C₂₁H₁₆ClNOS, 4‐(2‐hy­droxy­phenyl)‐2‐(4‐tolyl)‐2,3‐di­hydro‐1,5‐ben­zo­thia­zepine, C₂₂H₁₉NOS, and 4‐(2‐hydroxyphenyl)‐2‐(3‐methoxy­phenyl)‐2,3‐di­hydro‐1,5‐benzo­thia­zepine, C₂₂H₁₉NO₂S, the central seven‐membered heterocyclic rings adopt twist‐boat conformations in which the N atoms are involved in strong intramolecular hydrogen bonds with the hydroxyl H atoms, resulting in six‐membered rings.     

Di­bromo­[(–)‐sparteine‐κ2N,N′]­zinc(II)

In the title compound, di­bromo­[(6R,7S,8S,14S)‐1,3,4,7,7a,8,9,10,11,13,14,14a‐dodeca­hydro‐7,14‐methano‐2H,6H‐dipyrido­[1,2‐a:1′,2′‐e][1,5]­diazo­cine‐κ²N,N′]­zinc(II), [ZnBr₂(C₁₅H₂₆N₂)], the chiral nitro­gen‐chelating alkaloid (?)‐l ‐sparteine acts as a bidentate ligand, with two bromide ligands occupying the remaining coordination sites, producing a slightly distorted tetrahedral structure. The dihedral angle between the N—Zn—N and Br—Zn—Br planes is 82.4 (1)°. The distortion of the tetrahedral coordination is demonstrated by the fact that the midpoint of the N?N line does not lie in the Br—Zn—Br plane, but is tilted towards one of the N atoms by 0.164 Å. Similarly, the midpoint of the Br?Br line is tilted towards one of the Br atoms by 0.117 Å.     

2‐Chloro­phenyl 3‐nitro­benzene­sulfonate and 2,4‐di­chloro­phenyl 3‐nitro­benzene­sulfonate: supramole­cular aggregation through C–H⋯O, π–π and van der Waals interactions

In 2‐chloro­phenyl 3‐nitro­benzene­sulfonate, C₁₂H₈ClNO₅S, and 2,4‐di­chloro­phenyl 3‐nitro­benzene­sulfonate, C₁₂H₇Cl₂NO₅S, weak C—H⋯O interactions generate S(5), S(6) and (7) rings. The supramolecular aggregation is completed by the presence of π–π interactions and intermolecular van der Waals short contacts.     

β‐Pyridinium di­chloro­iodide

The β modification of pyridinium di­chloro­iodide, C₅H₆N⁺·Cl₂I^?, was obtained as yellow crystals by the reaction of (C₅NH₅)AuCl₃, C₅H₆N⁺·Cl^? and I₂ in a vacuum‐sealed ampoule. The di­chloro­iodide ion is nearly symmetric and linear with I—Cl bond lengths of 2.544 (3) and 2.550 (3) Å and a Cl—I—Cl angle of 179.68 (12)°.     

(1R,2R)‐1,2‐Di­phenyl‐1,2‐bis(8‐quinoline­sulfonyl­amino)ethyl­enedi­amine–acetone (1/1)

The crystal structure of the new chiral complex (1R,2R)‐1,2‐di­phenyl‐1,2‐bis(8‐quinoline­sulfonyl­amino)‐ ethyl­enedi­amine–acetone (1/1), C₃₂H₂₆N₄O₄S₂^.C₃H₆O, is reported. The conformation of the C₃₂H₂₆N₄O₄S₂ (BQSDA) mol­ecule is determined by a bifurcated N—H?N hydrogen‐bond system. The acetone of solvation is linked to the BQSDA mol­ecule by an N—H?O hydrogen bond.     

The diastereoisomers methyl 5‐(S)‐[2‐(R)/(S)‐methoxycarbonyl)‐2,3,4,5‐tetrahydropyrrol‐1‐ylcarbonyl]‐1‐(4‐methylphenyl)‐4,5‐dihydropyrazole‐3‐carboxylate

The title diastereoisomers, methyl 5‐(S)‐[2‐(S)‐methoxy­carbonyl)‐2,3,4,5‐tetra­hydro­pyrrol‐1‐yl­carbonyl]‐1‐(4‐methyl­phenyl)‐4,5‐di­hydro­pyrazole‐3‐carboxyl­ate and methyl 5‐(S)‐[2‐(R)‐methoxycarbonyl)‐2,3,4,5‐tetrahydropyrrol‐1‐ylcarbonyl]‐1‐(4‐methyl­phenyl)‐4,5‐di­hydro­pyrazole‐3‐carboxylate, both C₁₉H₂₃N₃O₅, have been studied in two crystalline forms. The first form, methyl 5‐(S)‐[2‐(S)‐methoxy­carbonyl)‐2,3,4,5‐tetrahydropyrrol‐1‐ylcarbonyl]‐1‐(4‐methylphenyl)‐4,5‐di­hydro­pyrazole‐3‐carboxyl­ate–methyl 5‐(S)‐[2‐(R)‐methoxy­carbonyl)‐2,3,4,5‐tetra­hydro­pyrrol‐1‐yl­carbonyl]‐1‐(4‐methylphenyl)‐4,5‐dihydropyrazole‐3‐carboxylate (1/1), 2(S),5(S)‐C₁₉H₂₃N₃O₅·2(R),5(S)‐C₁₉H₂₃N₃O₅, contains both S,S and S,R isomers, while the second, methyl 5‐(S)‐[2‐(S)‐methoxycarbonyl)‐2,3,4,5‐tetrahydro­pyrrol‐1‐ylcarbonyl]‐1‐(4‐methyl­phenyl)‐4,5‐di­hydro­pyrazole‐3‐carboxyl­ate, 2(S),5(S)‐C₁₉H₂₃N₃O₅, is the pure S,S isomer. The S,S isomers in the two structures show very similar geometries, the maximum difference being about 15° on one torsion angle. The differences between the S,S and S,R isomers, apart from those due to the inversion of one chiral centre, are more remarkable, and are partially due to a possible rotational disorder of the 2‐­(methoxycarbonyl)tetrahydropyrrole group.     

Disappearance of intramolecular stacking due to one‐atom movement or increment of a `propyl­ene linker' in pyrazolo­[3,4‐d]­pyrimidine‐based ­flexible models

In the crystal structures of 4,6‐di­methyl­thio‐1‐[3‐(4,6‐di­methyl­thio‐2H‐pyra­zolo­[3,4‐d]­py­rimi­din‐2‐yl)­propyl]‐1H‐py­ra­­zolo­[3,4‐d]­py­rimi­dine, C₁₇H₂₀N₈S₄, and 1‐[4‐(4‐meth­oxy‐6‐methyl­thio‐1H‐pyra­zolo­[3,4‐d]py­rimi­din‐1‐yl)­butyl]‐5‐meth­yl‐6‐methyl­thio‐4,5‐di­hydro‐1H‐pyra­zolo­[3,4‐d]py­rimi­din‐4‐one, C₁₈H₂₂N₈O₂S₂, only intermolecular stacking due to aromatic π–π interactions between pyrazolo­[3,4‐d]­pyrimidinerings is present.     

3,6‐Di­chloro‐4‐[2‐(4‐thia­morpholino)­ethanesulfanyl]­pyridazine and 3,6‐bis­(pyrazol‐1‐yl)‐4‐[2‐(4‐thia­mor­pho­lino)­ethanesulfanyl]­pyridazine

The trans–trans conformations adopted by the derivatized bis­(bidentate) chelating N₄‐donor ligand 3,6‐bis­(pyrazol‐1‐yl)‐4‐[2‐(4‐thia­morpholino)­ethanesulfanyl]­pyridazine, C₁₆H₁₉N₇S₂, and an intermediate in its formation, 3,6‐di­chloro‐4‐[2‐(4‐thia­morpholino)­ethanesulfanyl]­pyridazine, C₁₀H₁₃Cl₂N₃S₂, con­trast with the cis–cis conformation found previously for 3,6‐bis­(thio­phen‐2‐yl)­pyridazine [Ackers, Blake, Hill & Hubberstey (2002). Acta Cryst. C 58 , o640–o641], which places all four heteroatoms on the same side of the mol­ecule.